Change history 16 May 2025 Editors Note: Readers are alerted that concerns have been raised regarding the statistical analysis presented in this article
Explain when symptoms began, the current medication and dose, the date of the last dose, and whether symptoms followed a dose increase
Shortage Status Changes The FDA declared the semaglutide shortage resolved in February 2025
Oral and injectable Ozempic are not interchangeable
FEHB Plan Coverage Weight-loss drugs are classified as GLP-1 (glucagon-like peptide-1) receptor agonists, and the ones approved by the FDA include Qsymia, Contrave, Saxenda, Wegovy, and Zepbound
Anna Gevorgyan and alleges that the six- to seven-hour surgery involved improper administration and monitoring of anesthesia, resulting in acute toxic encephalopathy shortly after discharge